Keywords: Roche, Genentech, Perjeta, Pertuzumab, Breast cancer, USA, FDA

FDA backs Roche's personalized breast cancer therapy Perjeta

Article | 11 June 2012

Print This

The US Food and Drug Administration on Friday approved Swiss drug major Roche (ROG: SIX) subsidiary Genentech’s Perjeta ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in